Mersana Therapeutics Inc. (MRSN)
NASDAQ: MRSN
· Real-Time Price · USD
7.20
0.03 (0.42%)
At close: Sep 26, 2025, 10:57 AM
0.42% (1D)
| Bid | 7.14 |
| Market Cap | 35.91M |
| Revenue (ttm) | 34.77M |
| Net Income (ttm) | -74.04M |
| EPS (ttm) | -14.79 |
| PE Ratio (ttm) | -0.49 |
| Forward PE | -0.7 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 7.29 |
| Volume | 5,705 |
| Avg. Volume (20D) | 104,722 |
| Open | 7.22 |
| Previous Close | 7.17 |
| Day's Range | 7.18 - 7.34 |
| 52-Week Range | 5.21 - 70.75 |
| Beta | 0.85 |
| Ex-Dividend Date | n/a |
About MRSN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MRSN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MRSN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsMersana Therapeutics Inc. is scheduled to release its earnings on
Nov 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-20.61%
Mersana Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
4 months ago
-17.05%
Mersana Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results.
1 month ago · seekingalpha.com
Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call TranscriptMersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Brian C. DeSchuytner - Senior VP, CFO & COO Jason Fredette - Senior Vice Pres...
